MALT1 mediates the activation of NF-κB in response to antigen receptor signaling. MALT1, in association with BCL10 and CARD11, functions as a scaffolding protein to activate the IKK complex. Additionally, MALT1 is a paracaspase that targets key proteins in a feedback loop mediating termination of the NF-κB response; thus promoting activation of NF-κB signaling. 
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Background
MALT1 as a critical mediator of B-cell receptor signaling
The mucosa-associated lymphoid tissue lymphoma translocation 1 (MALT1) gene was first identified in the recurrent t(11;18)(q21;q21) in MALT lymphomas 1 . Resulting fusion product contains the N-terminal portion of cellular inhibitor of apoptosis 2 (cIAP2 or API2) and the Cterminal portion of MALT1. MALT1 is also translocated to the immunoglobulin heavy-chain gene enhancer in MALT lymphomas, leading to aberrant expression of the protein 2, 3 . Notably MALT1 transgenic mice develop MALT lymphomas histologically and molecularly analogous to the human disease 4 . MALT1 also plays a critical role in the activated B-cell subtype of diffuse large B-cell lymphoma (ABC-DLBCL) [5] [6] [7] , and indeed MALT1 transgenic mice develop an ABC-DLBCL like disease when crossed into a p53 null background 4 .
MALT1 forms a complex with the B-Cell CLL/Lymphoma 10 (BCL10) and caspase recruitment domain family, member 11 (CARD11) 8 . As part of this CARD11-BCL10-MALT1 (CBM) complex, MALT1 transduces signals from the B-cell receptor (BCR) and T-cell receptor (TCR), NK-cell and B cell-activating factor receptors 9 . Upon BCR engagement, a cascade of tyrosine kinase phosphorylation activates PI3K, which in turn activates PDK1 and BTK, and then PLC-γ2 to produce DAG and Ca 2+ and activate PKC-β 8, 10 ( Figure 1A) . PKC-β then phosphorylates CARD11 promoting a conformational change that enables interaction with BCL10 and MALT1 9 . Once this complex is formed, TRAF6 recruitment and polyubiquitylation of MALT1 and BCL10 promote the binding of IKKγ and TAK1 8, 11 ( Figure 1A) . Next IKKγ complexes with IKKα and IKKβ, which is phosphorylated and activated by TAK1, to phosphorylate the IκB proteins and induce their proteolytic degradation. NF-κB proteins can then translocate to the nucleus where they activate genes involved in proliferation, apoptosis inhibition and inflammation 8, 11 ( Figure 1A) . Remarkably, c-REL nuclear translocation is dependent on MALT1 activity, while it is dispensable for RELA activation [12] [13] [14] .
Accordingly, studies of MALT1 knockout mice indicated its essential role in antigenreceptor-induced NF-κB activation, cytokine production, and proliferation in T-and B-cells 15, 16 .
MALT1 knockout mice also exhibited impaired proliferation of splenic B-cells upon LPS stimulation 15 . Moreover BCL10 interacts with IRAK1 and transduces signaling through interaction with MALT1 upon LPS treatment in macrophages 17 ( Figure 1A ). These findings may
Research. 
Clinical-Translational Advances
MALT1 protease activity inhibition in ABC-DLBCL
DLBCLs are a heterogeneous group of diseases. Among them, the ABC subtype, characterized by constitutive NF-κB signaling, is most resistant to current chemotherapy regimens and therefore the most clinically challenging 27 . MALT1 is not mutated or translocated in DLBCL, although its locus is frequently affected by copy number gain in ABC-DLBCL patients 28 . An shRNA screening identified several BCR pathway components as essential for ABC-DLBCL including: MALT1, CARD11, BCL10 and IKKβ 7 and led to the discovery of activating mutations in CARD11, CD79A/B and MyD88 in ABC-DLBCL patients [29] [30] [31] . Exposure of ABC-DLBCLs to z-VRPR-fmk, a peptide inhibitor of MALT1 paracaspase activity was sufficient to inhibit growth of ABC-DLBCL cells 5, 6 . However, whereas z-VRPR-fmk is an excellent tool compound, it is not suitable for clinical use given that its effects can only be observed at 50-75 μM in cell culture, maybe due to poor cell penetrance.
In an effort to identify more clinically tractable MALT1 inhibitors, Nagel and colleagues identified the phenotiazines mepazine, thioridazine and promazine as reversible small inhibitors of MALT1 protease activity 32 . These phenothiazines also inhibited MALT1 downstream signaling and proliferation of ABC-DLBCL cell lines and xenografts 32 . Phenotiazines are dopamine D2 receptor antagonists and have been used as anti-psychotic and sedative drugs 33 . Thioridazine, the only of these drugs still in use, is generally restricted to patients that do not respond to other anti-psychotic drugs due to concerns about cardiotoxicity and retinopathy 34 . Repurposing of these drugs for treatment of ABC-DLBCL has been proposed although carries the risk of offtarget effects.
Fontán and colleagues identified novel MALT1 protease inhibitors by screening small molecule libraries using an in vitro active form of MALT1 13 . The most biologically potent inhibitor identified, "MI-2", exhibited irreversible and specific binding to MALT1 and suppressed its protease function in vitro and in vivo. MI-2 induced nuclear depletion of c-REL and suppressed NF-κB activity 13 . Most notably, MI-2 was non-toxic to mice, and displayed potent and specific activity against ABC-DLBCL cells in vitro and xenotransplanted in vivo 13 . The compound was also specifically effective against primary human non-GCB DLBCLs ex vivo 13 .
Hence MI-2 may represent a potentially clinically useful MALT1 inhibitor.
Finally, monoubiquitylation of MALT1 on Lys644 activates the protease function of MALT1. Expression of a non-ubiquitylatable MALT1(K644R) mutant reduced survival of ABC-DLBCL cell lines 35 . Targeting the ubiquitin ligase responsible for this activation, currently unknown, might also disrupt MALT1 activity.
Clinical context for translation of MALT1 targeted therapy
Biological dependency on BCR signaling is a central feature of several types of B-cell neoplasms 36 and its inhibition has been proposed as a strategy to treat lymphomas. A number of BCR pathway inhibitors are in development (Figure 2 Additionally, some DLBCL cell lines, not classified as ABC-DLBCL although BCR-dependent, present PI3K activation that could potentially trigger the CBM complex 42 . MALT lymphoma patients with t(11;18)(q21;q21), that exhibit unfavorable clinical outcome 43 , might also benefit from MALT1 proteolytic inhibition by preventing API2-MALT1 aberrant proteolytic activation of NIK and constitutive non-canonical NF-κB signaling 24 . Interestingly, MALT1 has been shown to contribute to the encephalitogenic potential of Th17 cells in a murine model of multiple sclerosis (MS) 44 ; while MALT1 deficiency protects mice from developing clinical symptoms of MS including demyelination 45 . Moreover, genome-wide association studies have determined MALT1 as a risk locus for multiple sclerosis 46 . MALT1 paracaspase inhibition needs to be explored in these settings.
Because MALT1 is involved in the immune response 8, 10, 11 , it will be important to monitor immune competency after administration of inhibitors of its activity. In particular since an autosomal recessive form of combined immunodeficiency has been associated with homozygous mutation of MALT1 in one family. This mutation led to loss of protein expression 50 .
How MALT1 paracaspase activity inhibition will influence the functioning of the immune system from the clinical standpoint is not known and will be important to evaluate when MALT1 inhibitor 
MALT1 inhibitors in rational combination therapies
Lymphomas are genetically complex, with individual tumors featuring a variety of genetic alterations including gain and loss of genomic regions, translocations and point mutations 36, 51 .
Hence targeting a single oncogenic pathway in these tumors is unlikely to be curative.
Moreover many lymphomas exhibit genomic instability and on-going somatic hypermutation 36 , which might increase the opportunity for acquired resistance to emerge. Both of these scenarios underline the importance of developing rational combinatorial therapy regimens to more effectively and completely eradicate lymphomas.
ABC-DLBCLs are more resistant to current chemotherapy regimens 27 . It is possible that 
